HIV Drugs Market Expected to Reach $51.1 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “HIV Drugs Market," The HIV drugs market size was valued at $32.8 billion in 2022, and is estimated to reach $51.1 billion by 2032, growing at a CAGR of 4.5% from 2023 to 2032. HIV stands for human immunodeficiency virus. HIV attacks the immune system of the human body. It weakens the immune system by destroying CD4 T cells, a type of white blood cell that plays a crucial role in the immune response. As a result, the body becomes less able to fight off infections and diseases. Therefore, HIV makes a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom), or through sharing injection and drug equipment.

HIV are treated by antiretroviral drugs (HIV drugs). These drugs work by slowing down the replication of the virus in the body, thereby reducing the viral load and preserving the immune system. HIV treatment often involves the multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, and HIV integrase strand transfer inhibitors.

Alarming rise in the in cases of HIV, as well as increase in the number of research regarding HIV drives the growth of the HIV drugs market size. For instance, according to the World Health Organization (WHO), July 2023, HIV remains a major global public health issue and advanced HIV disease remains a persistent problem in the HIV response. According to same source, there were an estimated 39.0 million [33.1–45.7 million] people living with HIV at the end of 2022. And the 630,000 [480,000–880,000] people died from HIV-related causes and 1.3 million [1.0–1.7 million] people acquired HIV in 2022. 

Moreover, the increase in initiatives taken by various organizations and government for reducing the burden of the HIV diseases and rise in number of clinical trials of HIV drugs are the HIV drugs market trends that drive the growth of market. In addition, rise in funding to conduct R&D activities for the development of novel HIV drugs and increase in awareness regarding HIV are the key factors that drive the growth of the market in developing countries such as India and China. 

Furthermore, rise in R&D investments; significant increase in capital income in developed countries; and adoption of developmental strategies such as product launch, collaboration, merger, acquisition, and agreement by key players to stay competitive in the market foster the growth of the HIV drugs market share. For instance, in February 2023, ViiV Healthcare, a subsidiary of GlaxoSmithKline plc., announced the European Commission has granted Marketing Authorization for Triumeq, a dispersible tablet formulation of the fixed-dose combination of abacavir, dolutegravir, and lamivudine for the treatment of pediatric patients weighing 14 kg to 25 kg with human immunodeficiency virus type 1 (HIV-1). 

On the basis of medication class, the market is categorized into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, and HIV integrase strand transfer inhibitors. The multi-class combination drugs segment is expected to witness the highest CAGR during the forecast period, owing to a rise in multi-class combination drugs product in pipeline and rise in preference of healthcare professional for multi-class combination drugs against HIV. 

On the basis of distribution channel, it is segregated into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. The online pharmacies segment is expected to witness the highest CAGR during the forecast period, owing to convenience in shopping, increase in e-commerce sales, improvements in logistics services, and ease in payment options. In addition, the easy accessibility and heavy discounts & offer provided by these online platforms drives the growth of HIV drugs market share during forecast period.

On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific and LAMEA. Asia-Pacific is expected to witness the highest CAGR during the forecast period due to increase in awareness regarding HIV, unmet medical demand, surge in healthcare expenditure, and increase in cases of HIV. 

Key findings of the study

• On the basis of medication class, the multi-class combination drugs segment held the largest share in the HIV drugs industry in 2022.
• On the basis of distribution channel, the hospital pharmacies dominated the HIV drugs industry in 2022.
• On the basis of region, North America was the major shareholder in 2022 in HIV drugs market analysis. However, Asia-Pacific is expected to witness the highest CAGR during the HIV drugs market forecast period